Название продукции:2-fluoro-9H-purin-6-amine

IUPAC Name:2-fluoro-9H-purin-6-amine

CAS:700-49-2
Молекулярная формула:C5H4FN5
Чистота:98%
Номер в каталоге:CM112176
Молекулярная масса:153.12

Упаковочная единица Доступно для заказа Цена ($) Количество
CM112176-5g in stock ŪƐ
CM112176-10g in stock ƚŸŞ
CM112176-25g in stock ƐȖƚ

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:700-49-2
Молекулярная формула:C5H4FN5
Точка плавления:-
Smiles-код:NC1=C2N=CNC2=NC(F)=N1
Плотность:
Номер в каталоге:CM112176
Молекулярная масса:153.12
Точка кипения:676.9°C at 760 mmHg
Номер Mdl:MFCD01632749
Хранение:Keep in a tight container and store at ambient temperature

Category Infos

Purines
Purines are heterocyclic aromatic compounds composed of linked pyrimidine and imidazole rings. In mammals, purines are most commonly expressed in DNA and RNA (including the purines adenine and guanine), as well as single-molecule nucleotides (adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, and to a lesser extent guanosine triphosphate (GTP) and cyclic guanosine monophosphate (cGMP). Purines are also key elements of the following energy metabolism molecules: reduced nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate (NADPH), and coenzyme Q. Purines can also act as direct neurotransmitters; for example, adenosine may interact with receptors to modulate cardiovascular and central nervous system (CNS) function.
purine wholesale
Find trusted purine wholesaler. Any requirements and problems can ask us at any time.

Column Infos

Islatravir and Lenacapavir
Gilead and Merck announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class , long-acting HIV capsid inhibitor. At 24 weeks, the novel investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA <50 copies/mL), which is a secondary endpoint of the study. Results of the primary endpoint (HIV-1 RNA ≥50 copies/mL (c/mL) showed that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of >50 copies/mL at Week 24;the participant later suppressed on islatravir and lenacapavir at Week 30.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.